Apie programą
Europos Komisijos kvietimai
Tarptautiniai renginiai
Partnerių paieška
Dalyvavimo statistika
Nemokamos konsultacijos
Parama rengti paraiškas
Parama susitikti konsorciumams
Parama ieškoti partnerių
Prizai

Inovatyvios medicinos iniciatyva – IMI2

Konsultuoja teminės srities atstovė, NCP: Edita Bagdonaitė, Šis el. pašto adresas yra apsaugotas nuo šiukšlių. Jums reikia įgalinti JavaScript, kad peržiūrėti jį.

Kvietimo identifikatorius ir pavadinimasFinansavimo schemos kodasKvietimo paskelbimo dataParaiškos priimamos iki
(pirmojo/antrojo etapo paraiškų priėmimo data, jei taikoma dviejų pakopų schema)

IMI2-2018-14-01: Targeted immune intervention for the management of non-response and relapse 

RIA

2018-03-15

(2018-06-14/2018-12-11)

IMI2-2018-14-02: Non-invasive clinical molecular imaging of immune cells 

RIA

2018-03-15

(2018-06-14/2018-12-11)

IMI2-2018-14-03: Development of a platform for federated and privacy-preserving machine learning in support of drug discovery

RIA

2018-03-15

(2018-06-14/2018-12-11)

IMI2-2018-14-04: Centre Of Excellence – Remote Decentralised Clinical Trials

RIA

2018-03-15

(2018-06-14/2018-12-11)

IMI2-2018-15-01: Integrated research platforms enabling patient-centric drug development

IMI2-RIA 

2018-07-18

(2018-10-24/2019-05-15)

IMI2-2018-15-02: Blockchain Enabled Healthcare

IMI2-RIA 

2018-07-18

(2018-10-24/2019-05-15)

IMI2-2018-15-03: Microenvironment imposed signatures in tissue and liquid biopsies in immune- mediated diseases

IMI2-RIA 

2018-07-18

(2018-10-24/2019-05-15)

IMI2-2018-15-04: Emerging translational safety technologies and tools for interrogating human immuno-biology

IMI2-RIA 

2018-07-18

(2018-10-24/2019-05-15)

IMI2-2018-15-05: Development and validation of translational platforms in support of synaptopathy drug discovery

IMI2-RIA 

2018-07-18

(2018-10-24/2019-05-15)

IMI2-2018-15-06: Digital endpoints in neurodegenerative and immune-mediated diseases

IMI2-RIA 

2018-07-18

(2018-10-24/2019-05-15)

IMI2-2018-15-07: AMR Accelerator programme Pillar A: Capability Building Network to accelerate and validate scientific discoveries

IMI2-RIA 

2018-07-18

(2018-10-24/2019-05-15)

IMI2-2018-15-08: AMR Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic

IMI2-RIA

2018-07-18

(2018-10-24/2019-05-15)

IMI2-2018-16-01: Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for TB that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

IMI2-RIA

2018-07-18

2018-10-24

IMI2-2018-16-02: Progress novel assets (one FTIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs

IMI2-RIA

2018-07-18

2018-10-24

IMI2-2018-16-03: Discover and progress novel assets with new mechanisms of action (one preNME for TB and one preNME for NTM) and biomarkers for TB and NTM infection

IMI2-RIA

2018-07-18

2018-10-24

IMI2-2018-16-04: Determination of gepotidacin levels in tonsils and prostatic tissue

IMI2-RIA

2018-07-18

2018-10-24

IMI2-2018-16-05: Infection site targeting, antibiotic encapsulated in nanoparticles for treating extracellular bacterial infections

IMI2-RIA

2018-07-18

2018-10-24

IMI2-2018-16-06: Functional Ethionamide boosters: a novel combination for tuberculosis therapy

IMI2-RIA

2018-07-18

2018-10-24

IMI2-2018-16-07: Intravenous treatments of serious infections (urinary tract infections, intra-abdominal infections & hospital-acquired pneumonia/ventilator associated pneumonia) caused by Gram(-) bacteria (Enterobacteriaceae +/- Pseudomonas and/or Acinetobacter)

IMI2-RIA

2018-07-18

2018-10-24


© MOKSLO, INOVACIJŲ IR TECHNOLOGIJŲ AGENTŪRA, VALSTYBĖS BIUDŽETINĖ ĮSTAIGA. DUOMENYS KAUPIAMI IR SAUGOMI JURIDINIŲ ASMENŲ REGISTRE.
A. GOŠTAUTO 12-219, LT-01108 VILNIUS. TEL. +370 (5) 2644708; FAKSAS +370 (5) 2312292; EL. PAŠTAS Šis el. pašto adresas yra apsaugotas nuo šiukšlių. Jums reikia įgalinti JavaScript, kad peržiūrėti jį.